Caterpillar Arterial Embolization Device Post-Market Study

STATUS

Recruiting
participants needed

50
sponsor

C. R. Bard

Updated on 19 February 2024

See if I qualify

Summary

The primary objective of this study is to evaluate the performance and safety of the Caterpillar Arterial Embolization Device when used for arterial embolization in the peripheral vasculature in a real world, on-label application.

Description

The post-market study is a prospective, multi-center, single-arm, real world study of the Caterpillar Arterial Embolization Device. Enrollment will continue until up to fifty (50) subjects have been treated with the Caterpillar Arterial Embolization Device at up to 20 investigational sites in the United States.

Details

Condition	Embolization
Age	18years - 100years
Treatment	Caterpillar™ Arterial Embolization Device
Clinical Study Identifier	NCT04244370
Sponsor	C. R. Bard
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Subject or Legally Authorized Representative (LAR) must voluntarily sign and date the approved Informed Consent Form (ICF) prior to collection of study-specific data or performance of study-specific procedures
	Subject must be either male or non-pregnant female 18 years of age with an expected lifespan sufficient to allow for completion of all study procedures
	Subject must be willing and able to comply with protocol requirements, including all study visits and procedures
	Subject must require peripheral vascular occlusion at an arterial target embolization site(s) that can be treated with the Caterpillar Arterial Embolization Device according to the Instructions for Use (IFU). Note: Per Investigator discretion, up to five (5) Target Embolization Sites may be treated with up to ten (10) study devices per subject
	Angiographic Inclusion Criteria
	\. The target embolization site(s) must be located in a native arterial
	vessel(s) with the intended arterial vessel diameter ranges shown in the IFU
	as assessed by the Investigator (via visual estimate)
	\. The target embolization site(s) must have a landing zone sufficient to
	accommodate the device implant lengths shown in the IFU
Exclusion Criteria
	The subject's access vessel(s) preclude safe insertion of the delivery catheter
	The subject's target embolization site(s) is located within a vein
	The subject's target embolization site(s) is located within the head, neck, heart or coronary vessels
	The subject's target embolization site(s) is located across highly locomotive joints or muscle beds (e.g. elbow, hip, knee, shoulder, thoracic inlet/outlet)
	The subject's target embolization site(s) is located in a high-flow vessel where, in the opinion of the Investigator, there may be significant risk of migration and unintended (non-target site) occlusion
	The subject has a known allergy or hypersensitivity to contrast media that cannot be adequately pre-medicated
	The subject has a known allergy or hypersensitivity to any of the device materials including: cobalt, chromium, nickel, titanium, platinum, iridium, polyurethane or polyethylene
	The subject has planned use of anticoagulant (e.g. direct thrombin inhibitors, factor Xa inhibitors, vitamin K antagonists) or antiplatelet therapy before, during and/or after treatment with the study device, which, in the opinion of the Investigator, would clinically interfere with the study endpoints
	The subject has a known uncontrolled blood coagulation or bleeding disorder
	The subject has an unresolved systemic infection
	The subject's required pre-operative laboratory tests and/or physical examination indicate abnormal results, which, in the opinion of the Investigator, would clinically interfere with the study endpoints
	The subject has a connective tissue disorders (e.g. Ehlers-Danlos Syndrome), arteritis (e.g. Takayasu's Disease) or another circulatory disorder, which, in the opinion of the Investigator, would clinically interfere with the study endpoints
	The subject has another medical condition which, in the opinion of the Investigator, may cause him/her to be non-compliant with the protocol, may confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up
	The subject is currently participating in an investigational drug or another device study that has not completed the study treatment or that clinically interferes with the study endpoints. Note: Studies requiring extended follow-up visits for products that were investigational, but have since become commercially available, are not considered investigational studies

How to participate?

Step 1 Connect with a study center

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Other language

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Caterpillar Arterial Embolization Device Post-Market Study

Summary

Description

Details

How to participate?

Similar trials to consider

Not finding what you're looking for?

Study AnnotationsStudy Notes

Add a private note

Study Definition

Add a private note

Caterpillar Arterial Embolization Device Post-Market Study

Summary

Description

Details

How to participate?

Similar trials to consider

Not finding what you're looking for?

Sign up as a volunteer to stay informed

Study AnnotationsStudy Notes

Add a private note

Send Notes

Study Definition

Add a private note